IL17A and myeloid sarcoma: Recent studies have revealed that IL-25 treatment reduces neuroinflammation and EAE disease severity [37,139], suggesting that IL-25 and IL-17, despite being members of the same cytokine family, play opposing roles in the pathogenesis of MS.